Elise Harcourt
Elise Harcourt writes for Upla Observer and other Independent Journal publications, covering IPOs, direct listings and exchange listings and SEC filings and securities regulation. Reporting under this byline is prepared by the Independent Journal editorial desk from primary sources, with AI assistance, and reviewed under our editorial policy.
6 articles

Teva Counts Its NYSE Direct Listing Among Q3 Milestones
Teva's Q3 release lists the NYSE direct listing of its ordinary shares beside an investment-grade return and $4.9 billion of refinancing. What it signals.

T3 Defense's S-1MEF Filing: A Late Step in Going Public
T3 Defense filed an S-1MEF on Oct. 22. Here is what that form means for an offering, and how two Reg A filings from the same week fit the picture.

Advasa Completes Nasdaq Direct Listing as ADBT After S-1
Tokyo-based fintech Advasa Holdings began trading on the Nasdaq Global Market as ADBT after its S-1 went effective August 11, with access via Japanese brokers.
Spectral Capital Ties Its Offering to Nasdaq Uplisting Requirements
Spectral Capital said Aug. 25, 2026 it would not proceed with a $15 million offering unless approved for Nasdaq. How uplisting requirements shape the deal.

Teva Replaces ADSs With an NYSE Direct Listing of Its Shares
Teva will swap its NYSE ADSs one-for-one for ordinary shares that start trading directly on the NYSE on September 14, 2026, with its Tel Aviv listing unchanged.
Duke Robotics Meets Uplisting Requirements With a $9.2M Raise
Duke Robotics moved from the OTCQB to the Nasdaq Capital Market in May 2026 with a $9.2 million unit deal. How the deal shows uplisting requirements at work.